Fatigue in sarcoidosis: A systematic review

Current Opinion in Pulmonary Medicine

Volumn 15, Issue 5, 2009, Pages 499-506

  De Kleijn, Willemien P E ^a,b   De Vries, Jolanda ^a,b,c   Lower, Elyse E ^d   Elfferich, Marjon D P ^b,d   Baughman, Robert P ^d   Drent, Marjolein ^b,d  

^a TILBURG UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c CPRLab   (Netherlands)

^d UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

Fatigue; Review; Sarcoidosis

Indexed keywords

ANALGESIC AGENT; AZATHIOPRINE; CORTICOSTEROID DERIVATIVE; DEXMETHYLPHENIDATE; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; STEROID;

CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE ASSOCIATION; EXERCISE TEST; FATIGUE; GAIT; HUMAN; MORBIDITY; PREVALENCE; PROGNOSIS; QUALITY OF LIFE; RATING SCALE; REVIEW; SARCOIDOSIS; SCORING SYSTEM; SEX DIFFERENCE; SYSTEMATIC REVIEW;

FATIGUE; GLUCOCORTICOIDS; HUMANS; PROGNOSIS; QUALITY OF LIFE; SARCOIDOSIS;

EID: 68949190806     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e32832d0403     Document Type: Review

References (43)

1. Cox C, Donohue J, Brown C, etal. Health-related quality of life of persons with sarcoidosis. Chest 2004; 125:997-1004.
2. James DG. Complications of sarcoidosis. Chronic fatigue syndrome. Sarcoidosis 1993; 10:1-3.
3. Michielsen HJ, Drent M, Peros-Golubicic T, De Vries J. Fatigue is associated with quality of life in sarcoidosis patients. Chest 2006; 130:989-994.
4. Chang B, Steimel J, Moller DR, et al. Depression in sarcoidosis. Am J Respir Crit Care Med 2001; 163:329-334.
5. Drent M, Wirnsberger RM, de Vries J, et al. Association of fatigue with an acute phase response in sarcoidosis. Eur Respir J 1999; 13:718-722.
6. Smets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995; 39:315-325.
7. Desmond PA, Hancock PA. Active and passive fatigue states. In: Hancock PA, Desmond PA, editors. Stress, workload, and fatigue. NJ: Lawrence Erlbaum Associates; 2001. pp. 455-465.
8. Michielsen HJ, De Vries J, Van Heck GL, et al. Examination of the dimensionality of fatigue: the construction of the Fatigue Assessment Scale (FAS). Eur J Psychol Assess 2004; 20:37-48.
9. De Vries J, Michielsen H, Van Heck GL, Drent M. Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS). Br J Health Psychol 2004; 9(Pt3):279-291.
10. De Vries J, Drent M. Quality of life and health status in sarcoidosis: a review of the literature. Clin Chest Med 2008; 29:525-532; ix.
11. Den Oudsten BL, Van Heck GL, De Vries J. Quality of life and related concepts in Parkinson's disease: a systematic review. Mov Disord 2007; 22:1528-1537. (Pubitemid 47477911)
12. Wirnsberger RM, Drent M, Hekelaar N, etal. Relationship between respiratory muscle function and quality of life in sarcoidosis. Eur Respir J 1997; 10:1450-1455.
13. Wirnsberger RM, de Vries J, Wouters EF, Drent M. Clinical presentation of sarcoidosis in The Netherlands: an epidemiological study. Neth J Med 1998; 53:53-60.
14. Wirnsberger RM, de Vries J, Breteler MH, et al. Evaluation of quality of life in sarcoidosis patients. Respir Med 1998; 92:750-756.
15. Drent M, Wirnsberger RM, Breteler MH, et al. Quality of life and depressive symptoms in patients suffering from sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1998; 15:59-66.
16. De Vries J, Van Heck GL, Drent M. Gender differences in sarcoidosis: symptoms, quality of life, and medical consumption. Women Health 1999; 30:99-114.
17. Wirnsberger RM, De Vries J, Jansen TL, et al. Impairment of quality of life: rheumatoid arthritis versus sarcoidosis. Neth J Med 1999; 54:86-95.
18. Cox CE, Donohue JF, Brown CD, etal. The sarcoidosis health questionnaire: a new measure of health-related quality of life. Am J Respir Crit Care Med 2003; 168:323-329.
19. Hoitsma E, De Vries J, van Santen-Hoeufft M, et al. Impact of pain in a Dutch sarcoidosis patient population. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20:33-39.
20. Brancaleone P, Perez T, Robin S, et al. Clinical impact of inspiratory muscle impairment in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21:219-227.
21. De Vries J, Rothkrantz-Kos S, van Dieijen-Visser MP, Drent M. The relationship between fatigue and clinical parameters in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21:127-136.
22. De Vries J, Drent M. Relationship between perceived stress and sarcoidosis in a Dutch patient population. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21:57-63.
23. Michielsen HJ, De Vries J, Drent M, Peros-Golubicic T. Psychometric qualities of the fatigue assessment scale in Croatian sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22:133-138.
24. Spruit MA, Thomeer MJ, Gosselink R, et al. Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. Thorax 2005; 60:32-38.
25. Baughman RP, Sparkman BK, Lower EE. Six-minute walk test and health status assessment in sarcoidosis. Chest 2007; 132:207-213.
26. Michielsen HJ, Peros-Golubicic T, Drent M, De Vries J. Relationship between symptoms and quality of life in a sarcoidosis population. Respiration 2007; 74:401-405. (Pubitemid 47093152)
27. Gvozdenovic BS, Mihailovic-Vucinic V, Ilic-Dudvarski A, et al. Differences in symptom severity and health status impairment between patients with pulmonary and pulmonary plus extrapulmonary sarcoidosis. Respir Med 2008; 102:1636-1642.
28. Lower EE, Harman S, Baughman RP. Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue. Chest 2008; 133:1189-1195.
29. Mols F, Vingerhoets AJ, Coebergh JW, van de Poll-Franse LV. Quality of life among long-term breast cancer survivors: a systematic review. Eur J Cancer 2005; 41:2613-2619.
30. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160: 736-755.
31. Yellen SB, Cella DF, Webster K, et al. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 1997; 13:63-74.
32. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111-117.
33. Afari N, Buchwald D. Chronic fatigue syndrome: a review. Am J Psychiatry 2003; 160:221-236.
34. Drent M, Verbraecken J, van der Grinten C, Wouters E. Fatigue associated with obstructive sleep apnea in a patient with sarcoidosis. Respiration 2000; 67:337-340.
35. Devigili G, Tugnoli V, Penza P, et al. The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain 2008; 131 (Pt7):1912-1925.
36. Goldstein DS, Robertson D, Esler M, et al. Dysautonomias: clinical disorders of the autonomic nervous system. Ann Intern Med 2002; 137:753-763. (Pubitemid 35265320)
37. Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006; 174:795-802.
38. Baughman RP, Lower EE, Drent M. Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them. Sarcoidosis Vasc Diffuse Lung Dis 2008; 25:76-89.
39. Minderhoud IM, Samsom M, Oldenburg B. Crohn's disease, fatigue, and infliximab: is there a role for cytokines in the pathogenesis of fatigue? World J Gastroenterol 2007; 13:2089-2093.
40. Yin Ho L, Chiu Mok C, Hung To C, et al. Rituximab for refractory rheumatoid arthritis: a 24-week open-label prospective study. Open Rheumatol J 2007; 1:1-4.
41. Fouchier SM, Moller GM, Van Santen-Hoeufft M, et al. Successful treatment with infliximab of a patient with refractory sarcoidosis. Ned Tijdschr Geneeskd 2004; 148:2446-2450.
42. Hoitsma E, Faber CG, van Santen-Hoeufft M, et al. Improvement of small fiber neuropathy in a sarcoidosis patient after treatment with infliximab. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23:73-77.
43. Keijsers R, Verzijlbergen J, van Diepen D, et al. 18F-FDG PET in sarcoidosis: an observational study in 12 patients with infliximab. Sarcoidosis Vasc Diffuse Lung Dis 2008; 12:143-150.